Compare FSTR & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | ALLO |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.3M | 452.6M |
| IPO Year | 1995 | 2018 |
| Metric | FSTR | ALLO |
|---|---|---|
| Price | $38.07 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | ★ $45.50 | $9.00 |
| AVG Volume (30 Days) | 29.8K | ★ 11.4M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $540,009,000.00 | N/A |
| Revenue This Year | $6.53 | N/A |
| Revenue Next Year | $4.30 | $180.53 |
| P/E Ratio | $37.13 | ★ N/A |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $25.66 | $0.65 |
| 52 Week High | $45.81 | $4.46 |
| Indicator | FSTR | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 17.76 |
| Support Level | $36.53 | N/A |
| Resistance Level | $38.92 | $2.22 |
| Average True Range (ATR) | 1.62 | 0.09 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 31.39 | 0.05 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).